Dominique Demolle to Unveil Cognivia AI-powered Innovations at DPharm Conference
Dominique Demolle, CEO of Cognivia, is set to deliver a captivating presentation at the upcoming DPharm conference which is scheduled for…
News
News
News
What the FDA’s Final Guidance on Covariates Means for Fighting the Placebo Response in RCTs: Our Article Published in ACRP Journal
The recently released final guidance by the U.S. Food & Drug Administration (FDA) on “Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products” introduces a new framework that is poised to transform the way statistical analyses are conducted in RCTs.
News
Covariate Adjustment in Randomized Clinical Trials Based on Latest FDA Guidance: Application to composite covariates
In May 2023, the FDA has unveiled its definitive guidance titled “Adjusting for Covariates in Randomized Clinical Trials (RCT) for Drugs…
News
Webinar: Patient Adherence and Engagement: Predicting Non-Adherence and Dropout RisksWebinar:
Patient adherence remains a significant challenge in clinical research and medical practice, affecting drug development, healthcare costs, and…
News
Cognivia expands its portfolio of predictive solutions introducing Compl-AI©™, an innovative solution that predicts the risk of patient nonadherence & dropout
Compl-AI is a predictive tool that helps clinical trial sponsors optimize patient recruitment and engagement strategies. Nonadherence in clinical trials and high rates of dropout make efficacy and safety more difficult to determine.
News
Year In Review
2022 was a year of remarkable success for Cognivia.
Thank you to our team, partners and clients for your continued support! Here are highlights from this year – from exciting company updates to thought leadership articles.